Targeted therapy has brought significant improvements to certain groups of patients with non-small cell lung cancer (NSCLC). Selecting patients who will benefit from targeted therapy can be performed using molecular profiling with next-generation sequencing (NGS) techniques. However, we still lack sufficient data on the feasibility and results of such profiling in real-world clinical practice, which was the focus of an analysis recently published in The Oncologist.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
